type 2 diabetic. Diabetes mellitus
Conditions
Interventions
Intervention 1: In the first group tablet Atorvastatin (40-80 milligram) daily will be prescribed. Intervention 2: In the second group tablet Atorvastatin (10-20 milligram) daily will be prescribed.
Treatment - Drugs
In the first group tablet Atorvastatin (40-80 milligram) daily will be prescribed
In the second group tablet Atorvastatin (10-20 milligram) daily will be prescribed
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences Daneshgah Square Tabriz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with type2 diabetes mellitus LDL>70 ; age>18y ;TG 1 mth) Exclusion criteria: type 1 diabetes Mellitus; chronic liver disease(liver enzymes more than 3 time the upper limit of normal , B or C Hepatitis ); renal failure Cr>2;pregnancy;lactation ; Chronic inflammatory diseases such as rheumatic diseases (rheumatoid arthritis and systemic lupus erythematosus); Patients with a history of anti-inflammatory drugs; In case of muscle pain and increased risk of rhabdomyolysis in patients with CPK elevation; unwillingness to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low density Lipoprotein. Timepoint: At baseline and after 3 months of treatment. Method of measurement: Test.;Cholestrol. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory markers. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test.;Coagulatory factor. Timepoint: At baseline and after 3 months of treatment. Method of measurement: test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mitra Niafar
Tabriz University of Medical Sciences
Outcome results
None listed